Celotnem

Celotnem is a synthetic peptide antibiotic that has been developed to combat antibiotic-resistant bacteria. It is a member of the cyclic lipopeptide family, which includes other antibiotics such as daptomycin and teixobactin. Celotnem is produced by fermentation of a genetically modified strain of Streptomyces lavendulae.

The mechanism of action of celotnem involves the inhibition of bacterial cell wall synthesis. It binds to the lipid II precursor, preventing the formation of peptidoglycan, a crucial component of the bacterial cell wall. This disruption leads to cell death in susceptible bacteria.

Celotnem has shown promising in vitro activity against a wide range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). However, its clinical efficacy and safety profile are still under investigation.

The development of celotnem has been driven by the increasing concern over antibiotic resistance. As traditional antibiotics become less effective, there is a growing need for new therapeutic options. Celotnem represents a potential solution, but further research is required to fully understand its potential and limitations.